Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.4.24.61 - nardilysin

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acute Coronary Syndrome
Nardilysin is a promising biomarker for the early diagnosis of acute coronary syndrome.
Nardilysin: A potential biomarker for the early diagnosis of acute coronary syndrome.
Reply: Nardilysin is a promising biomarker for the early diagnosis of acute coronary syndrome.
Response to Letter of Stephenson et al.: Nardilysin: A potential biomarker for the early diagnosis of acute coronary syndrome.
Adenocarcinoma
Nardilysin inhibits pancreatitis and suppresses pancreatic ductal adenocarcinoma initiation in mice.
Alzheimer Disease
Nardilysin in human brain diseases: both friend and foe.
Nardilysin prevents amyloid plaque formation by enhancing ?-secretase activity in an Alzheimer's disease mouse model.
Nardilysin, ADAM10, and Alzheimer's disease: of mice and men.
Reduced neuronal co-localisation of nardilysin and the putative alpha-secretases ADAM10 and ADAM17 in Alzheimer's disease and Down syndrome brains.
Retinoic acid-induced upregulation of the metalloendopeptidase nardilysin is accelerated by co-expression of the brain-specific protein p42(IP4) (centaurin ?1; ADAP1) in neuroblastoma cells.
Arthritis
Nardilysin is involved in autoimmune arthritis via the regulation of tumour necrosis factor alpha secretion.
Brain Diseases
Nardilysin in human brain diseases: both friend and foe.
Carcinogenesis
Nardilysin controls intestinal tumorigenesis through HDAC1/p53-dependent transcriptional regulation.
Carcinoma
Nardilysin protein promotes invasion of esophageal cell carcinoma (ESCC) cells through induction of MMP2 and MMP3. Immunohistochemical analysis of nardilysin in ESCC tissue.
Carcinoma, Hepatocellular
Nardilysin promotes hepatocellular carcinoma through activation of signal transducer and activator of transcription 3.
Cerebral Infarction
Clinical determination of serum nardilysin levels in predicting 30-day mortality among adults with malignant cerebral infarction.
Cholangiocarcinoma
Serum Nardilysin, a Surrogate Marker for Epithelial-Mesenchymal Transition, Predicts Prognosis of Intrahepatic Cholangiocarcinoma after Surgical Resection.
Coma
Clinical determination of serum nardilysin levels in predicting 30-day mortality among adults with malignant cerebral infarction.
Down Syndrome
Nardilysin in human brain diseases: both friend and foe.
Reduced neuronal co-localisation of nardilysin and the putative alpha-secretases ADAM10 and ADAM17 in Alzheimer's disease and Down syndrome brains.
Esophageal Neoplasms
NRD1, which encodes nardilysin protein, promotes esophageal cancer cell invasion through induction of MMP2 and MMP3 expression.
Fatty Liver
Deletion of nardilysin prevents the development of steatohepatitis and liver fibrotic changes.
Infections
Fasciola hepatica surface tegument: glycoproteins at the interface of parasite and host.
Leukemia
Heparin-binding epidermal growth factor-like growth factor: hypoxia-inducible expression in vitro and stimulation of neurogenesis in vitro and in vivo.
Melanoma
Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopes.
Myocardial Infarction
Increased serum nardilysin is associated with worse long-term outcome of ST-elevation myocardial infarction.
Neoplasms
Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopes.
Deficiency of Nardilysin in the Liver Reduces Serum Cholesterol Levels.
Nardilysin enhances ectodomain shedding of heparin-binding epidermal growth factor-like growth factor through activation of tumor necrosis factor-alpha-converting enzyme.
Nardilysin in human brain diseases: both friend and foe.
Nardilysin is involved in autoimmune arthritis via the regulation of tumour necrosis factor alpha secretion.
Nardilysin regulates inflammation, metaplasia, and tumors in murine stomach.
NRD1, which encodes nardilysin protein, promotes esophageal cancer cell invasion through induction of MMP2 and MMP3 expression.
Serum Nardilysin, a Surrogate Marker for Epithelial-Mesenchymal Transition, Predicts Prognosis of Intrahepatic Cholangiocarcinoma after Surgical Resection.
Neuroblastoma
Decreased expression of nardilysin in SH-SY5Y cells under ethanol stress and reduced density of nardilysin-expressing neurons in brains of alcoholics.
Expression and retinoid modulation of N-arginine dibasic convertase and an aminopeptidase-B in human neuroblastoma cell lines.
Retinoic acid-induced upregulation of the metalloendopeptidase nardilysin is accelerated by co-expression of the brain-specific protein p42(IP4) (centaurin ?1; ADAP1) in neuroblastoma cells.
Tubulin potentiates the interaction of the metalloendopeptidase nardilysin with the neuronal scaffold protein p42IP4/centaurin-?1 (ADAP1).
Pancreatitis
Nardilysin inhibits pancreatitis and suppresses pancreatic ductal adenocarcinoma initiation in mice.
Retinal Diseases
Regulation of ADAM10 and ADAM17 by Sorafenib Inhibits Epithelial-to-Mesenchymal Transition in Epstein-Barr Virus-Infected Retinal Pigment Epithelial Cells.
Stomach Neoplasms
Nardilysin and ADAM proteases promote gastric cancer cell growth by activating intrinsic cytokine signalling via enhanced ectodomain shedding of TNF-?
Stroke
Clinical determination of serum nardilysin levels in predicting 30-day mortality among adults with malignant cerebral infarction.